Atlas Venture
890 Winter Street
Suite 320
Waltham, MA 02451
USA
Telephone: +1.781.622.1700
Fax: +1.781.622.1701
Email: jfformela@atlasventure.com
Dr. Jean-Fran?ois Formela is a Partner and joined Atlas Venture in 1993 to help build the US life sciences franchise.
Previously, he was Senior Director, Medical Marketing and Scientific Affairs at Schering-Plough in the US. During his tenure there, he was responsible for the marketing of Intron A, Schering-Plough's alpha-interferon. In his last position at Schering-Plough, he directed the US Phase IV studies in all therapeutic areas, as well as the health economics, medical information, and biotechnology pre-marketing groups. As a medical doctor, Jean-François practiced emergency medicine at Necker University hospital in Paris.
Since joining Atlas Venture, Dr. Formela has been involved in the formation of companies such as Archemix, ArQule (NASDAQ: ARQL), Aureon Laboratories, Cellzome, deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM), Resolvyx Pharmaceuticals and SGX Pharmaceuticals (NASDAQ: SGXP). He was also an investor in Ciphergen Biosystems (NASDAQ: CIPH) and Nuvelo (NASDAQ: NUVO).
Dr. Formela currently serves on the Boards of Achillion Pharmaceuticals (NASDAQ: ACHN), Adnexus Therapeutics, ARCA Discovery, Proprius Pharmaceuticals, Resolvyx Pharmaceuticals and SGX Pharmaceuticals (NASDAQ: SGXP).
Dr. Formela received his MD from Paris University School of Medicine, and his MBA from Columbia University.